[ Ссылка ]
A side effect observed during preclinical studies of a potential heart drug is underpinning the development of a peptide that shows promise in restoring hair growth. Follicum AB CBO Gunnar Gårdemyr took time out during his busy partnering schedule at BIO-Europe Spring 2018 to update Scrip on the progress the company is making with FOL-005 which is currently in Phase I/II studies and available for out-licensing.
